

REMARKS

Claims 1-89 were pending. In response to the Examiner's restriction requirement, Applicant provisionally elects to pursue claims 1-23 and 78-79, Group I, with traverse.

Restriction Requirement

The Examiner requires Applicant to elect one of the following designated groups for examination:

Invention I, encompassing claims 1-23 and 78-79, "drawn to a dosage form comprising a thyroid hormone prepared under conditions of low compression, classified in class 424, subclass 464";

Invention II, encompassing claims 24-70 and 80-87, "drawn to a dosage form comprising a thyroid hormone admixed with a substantially non-volatile, pharmaceutically acceptable oil, classified in class 424, subclass 451"; and

Invention III, encompassing claims 71-77 and 88-89, "drawn to a dosage form comprising a thyroid hormone and a hydrophobic powder, classified in class 424, subclass 464."

(Office Action at page 2).

In an attempt to advance the prosecution of this application to allowance, Applicant provisionally elects Group I, encompassing claims 1-23 and 78-79 with traverse. Applicants reserve the right to prosecute claims 24-77, and 80-89 in a future divisional application.

Notwithstanding the foregoing, Applicants respectfully submit that Groups I, II, and III as set forth by the Examiner are amenable to being combined and that such further grouping would not impose a serious burden on the Examiner as Groups I, II, and III are drawn to related subject matter. For example, Groups I & III are classified as being in the same class and subclass. Applicants request that the Examiner reconsider this restriction requirement after an initial search has been conducted.

Applicant believes that the foregoing is a full and complete response to the Office Action of record.

Respectfully submitted,


Stephen C. Timmins, Esq.
Registration No. 48,481

Date: 1/17/02
WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100